Arthrosurface said last week that data from a study of its Ovo with inlay glenoid shoulder arthroplasty system showed strengths in pain relief, patient satisfaction and functional improvements in patients with glenohumeral arthritis.
The Franklin, Mass.-based company’s OvoMotion is a stemless total shoulder system is designed to minimize bone removal specifically for patients with painful or severely disabled shoulder joints from arthritis, traumatic events or avascular necrosis. It won FDA clearance in April 2019.
In the trial, the company’s Ovo with inlay glenoid shoulder arthroplasty system was used on 31 shoulders with an average follow-up of 43 months (follow-ups ranged from 24 months to 74). The trial had no intraoperative complications and no 90-day re-hospitalization.
Arthrosurface concluded that patients experienced pain relief, satisfaction and functional results for both eccentric and concentric glenoids, while also improving their range of motion. The company said there were no activity restrictions for patients treated with Ovo and there is a significantly lower risk of glenoid loosening.
The study, conducted by the department of orthopedic surgery at The Cleveland Clinic Foundation, was published in the Journal of Shoulder & Elbow Surgery.
“This truly is a revolutionary stemless total shoulder, which combines the concept of anatomic restoration with an aspherical head design, which more closely replicates the normal patient anatomy,” The Cleveland Clinic’s Dr. Anthony Miniaci said in prepared remarks. “This combination of an aspherical head and inlay glenoid has shown to be effective in not only active and younger patients but in all of those with glenohumeral arthritis even in the face of posterior subluxation and bone erosion.”